A PHASE I/II, OPEN-LABEL, MULTI-COHORT STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CEVOSTAMAB IN PRIOR B CELL MATURATION ANTIGEN-EXPOSED PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
This study will evaluate the efficacy, safety, and pharmacokinetics of cevostamab in participants with R/R MM. Sections 3.1 and 3.2 present the primary and secondary efficacy objectives for the study expressed using the estimand framework in accordance with the ICH E9(R1) statistical principles for clinical trials (FDA 2021b).
University of Colorado Hospital
Peter Forsberg, MD
Protocol Number: 22-0931
More information available at ClinicalTrials.gov: NCT05535244
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers